
Brian Cheng, an analyst from J.P. Morgan, maintained the Buy rating on TRex Bio, Inc.. The associated price target remains the same with $20.00. Brian Cheng’s rating is based on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TRXB | TRex Bio, Inc. | 9.39 | -4.61 | -32.93% |
| Name | Price | % Change | |
|---|---|---|---|
| $9.39 | -32.93% |

Brian Cheng, an analyst from J.P. Morgan, maintained the Buy rating on TRex Bio, Inc.. The associated price target remains the same with $20.00. Brian Cheng’s rating is based on

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of TRex Bio (TRXB) with an Overweight rating. TRex Bio offers a promising Treg-focused autoimmune platform, with TRB-061 in Phase 1b for atopic

JPMorgan initiated coverage of TRex Bio (TRXB) with an Overweight rating and $20 price target The firm believes TRex’s approach to regulatory T cell biology “holds attractive potential” by selectively

Stifel initiated coverage of TRex Bio (TRXB) with a Buy rating and $39 price target The firm believes regulatory T-cell modulation represents a new frontier for the treatment of autoimmune

The biotech IPO market continued to see activity last week, with Aspen Neuroscience and Bambusa Therapeutics making their public market debuts as investors showed continued interest in early-stage healthcare companies.

Wedbush analyst Martin Fan initiated coverage of TRex Bio (TRXB) with an Outperform rating and $30 price target The firm believes the Dupixent-experienced population in atopic dermatitis presents a growing

TRex Bio, Inc. ($TRXB) announced an update on their ongoing clinical study. TRex Bio, Inc. (TRXB) is running a Phase 1a/1b trial called “A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled, 3-Part

An update from TRex Bio, Inc. ( ($TRXB) ) is now available. On October 13, 2026, TRex Bio, Inc. implemented a fourth amended and restated certificate of incorporation in connection

Two new biotech names began trading last week, with Retension Pharmaceuticals and TRex Bio making their market debuts on October 9. Retension enters the public markets with a focus on
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.